



**Figure S1.** Uptake of synovial exosomes by human macrophages. Human macrophages were incubated with CFSE-labeled exosomes or PBS (negative control) at 37  $^{\circ}$ C. After 3 h of incubation, cells were fixed and nuclei were stained using Hoechst 33258. Images were analyzed using confocal microscope. The white arrow indicates cellular uptake of synovial exosomes. Scale bar = 40  $\mu$ m. DIC = differential interference contrast.



**Figure S2.** The effect of synovial exosomes on cell proliferation. Human macrophages differentiated from CD14<sup>+</sup> monocyte were treated with 20 ng/mL of M-CSF +40 ng/ml of sRANKL (positive control) or with 10% synovial exosomes, respectively. Exosomes were isolated from same volume of synovial fluid with RA, AS, gout, and OA patients. After 48 h of incubation, cell proliferation was measured using CCK-8. Data are presented as a fold change of cell proliferation compared to medium alone (negative control) and presented as the mean  $\pm$  SEM. \* p < 0.05 vs. medium alone, \*\* p < 0.01 vs. medium alone.



**Figure S3.** Treatment of a fixed number of exosomes with human macrophages and the effect of synovial exosomes on human osteoclastogenesis. Human macrophages were treated with a fixed number of exosomes isolated from RA or AS patients. After 9–10 d of incubation, cells were stained for TRAP expression and TRAP-positive multinucleated cells (MNCs) were counted. Data are presented as a fold change of osteoclast number compared to medium alone (negative control). Data are presented as the mean ± SEM.